Evidence map›Paper›PMID 28654869›Full record

ReviewJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2017

A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers.

Patricia I Mathias, Thomas H Connor, Clayton B'Hymer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Exposure to Antineoplastic Drugs in Occupational Settings: A Systematic Review of Biological Monitoring Data.International journal of environmental research and public health · 2022
    Pooled it
  2. Trial
  3. Observational
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patricia I MathiasU.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Division of Applied Research and Technology, Biomonitoring and Health Assessment Branch, Robert A. Taft Laboratories, 1150 Tusculum Avenue, Cincinnati, OH, 45226, United States. Electronic address: pmathias@cdc.gov.
Thomas H ConnorU.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Division of Applied Research and Technology, Biomonitoring and Health Assessment Branch, Robert A. Taft Laboratories, 1150 Tusculum Avenue, Cincinnati, OH, 45226, United States.
Clayton B'HymerU.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Division of Applied Research and Technology, Biomonitoring and Health Assessment Branch, Robert A. Taft Laboratories, 1150 Tusculum Avenue, Cincinnati, OH, 45226, United States.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

This review describes published high performance liquid chromatography/mass spectrometry (HPLC-MS) methods for the determination of anticancer drugs in human urine as non-invasive tool for monitoring of health care worker exposure to antineoplastic and cytotoxic drugs. HPLC-MS is a sensitive and specific method for analysis of anticancer drugs and their metabolites in biological fluids. In this review, a tabular summary and overview of published HPLC-MS methods are presented, as well as future trends and limitations in this area of research.

Indexed as

Antineoplastic AgentsBiomarkersChromatography, High Pressure LiquidHealth PersonnelHumansMass SpectrometryOccupational ExposureAntineoplastic AgentsBiomarkersAnticancer drugsAntineoplastic drugLiquid chromatography mass spectrometryOccupational biomonitoringUrinary biomarker

Identifiers

PMID28654869
PMCPMC5585056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.